The aim: The current study was designed for evaluation the effect of oral magnesium l-lactate supplementation on blood pressure and corrected QT interval in a sample of Iraqi women. Materials and methods: In this interventional prospective randomized trial, 58 female patients diagnosed with MetS according to the International Diabetic Federation (IDF) criteria and were randomly allocated to receive either placebo or magnesium l-lactate 84 mg, twice daily. Results: O#ce blood pressure showed a signi$cant drop in systolic blood pressure (SBP) (P<0.05), non-signi$cant decline in diastolic blood pressure (DBP), heart rate (HR), and pulse pressure (PP) (P>0.05), while ambulatory blood pressure monitoring (ABPM) recorded a signi$cant reduction in HR in patients on magnesium supplement. Also, there was a signi$cant decline in the SBP (P<0.05) and non-signi$cant decline in DBP and PP (P>0.05) in patients with masked hypertension on Mg supplement. The changes in corrected QT- interval had no signi$cant e"ect within Mg group (P>0.05). Conclusions: From above results, one can conclude that oral Mg l-lactate supplement can improve, to a certain extent, blood pressure of women with MetS. Further studies in this aspect may be required.

Ferritin is the main iron storage protein that plays an important role in iron homeostasis and is concerned with many physiological functions and pathologic disorders. Clinically, ferritin is mainly used as a biomarker for total body iron stores. Serum ferritin has a critical function in both iron deficiency and overload that related to the diagnosis and treatment. High levels of both serum and tissue ferritin are related to the coronary artery disorder, cancer, and bad results after stem cell transplantation. Less commonly, ferritin is related to other human diseases like the neurodegenerative complaints, sideroblastic anemias, and hemophagocytic disorder. Moreover, up to date research explains a novel function of ferritin that not related to the iron storage.